Update on Alpha‐1 Antitrypsin Deficiency in Liver Disease
Praveena Narayanan, Pramod K. Mistry – 30 June 2020
Highlights From the AASLD/EASL ALD Endpoints Conference 2019
Madeline Bertha, Haripriya Maddur – 30 June 2020
Risk Scores for Hepatocellular Carcinoma in Chronic Hepatitis B: A Promise for Precision Medicine
George V. Papatheodoridis, Thodoris Voulgaris, Margarita Papatheodoridi, W. Ray Kim – 30 June 2020
Cholangitis Lenta: What Hepatologists Need to Know
Adam L. Booth, Shehzad N. Merwat, Sheharyar K. Merwat, Heather L. Stevenson – 30 June 2020
Cause for Confusion: Noncirrhotic Hyperammonemic Encephalopathy
Avash Kalra, J. P. Norvell – 30 June 2020
Clinical Features of Patients Infected With Coronavirus Disease 2019 With Elevated Liver Biochemistries: A Multicenter, Retrospective Study
Yu Fu, Rui Zhu, Tao Bai, Ping Han, Qin He, Mengjia Jing, Xiaofeng Xiong, Xi Zhao, Runze Quan, Chaoyue Chen, Ying Zhang, Meihui Tao, Jianhua Yi, Dean Tian, Wei Yan – 30 June 2020
Risk Scores for Hepatocellular Carcinoma in Chronic Hepatitis B: A Promise for Precision Medicine
George V. Papatheodoridis, Thodoris Voulgaris, Margarita Papatheodoridi, W. Ray Kim – 30 June 2020
Fatal COVID‐19 in a Patient with End‐Stage Liver Disease Wait‐Listed for Liver Transplantation: An Evidence‐Based Review of COVID‐19 Screening Modalities Prior to Transplant
Yoona Rhee, Edie L. Chan, Sheila L. Eswaran, Costica Aloman, Martin Hertl, Carlos A.Q. Santos – 30 June 2020
It Is Not All About Pretransplant Factors: Posttransplant Complications Alter the Risk of Alcohol Relapse
Toshihiro Kitajima, Shunji Nagai, Dilip Moonka, Antu Segal, Marwan S. Abouljoud – 30 June 2020
Safety and Efficacy of Budesonide for Liver Transplant Immune Suppression: Results of a Pilot Phase 2a Trial
Khurram Bari, Shimul A. Shah, Tiffany E. Kaiser, Robert M. Cohen, Nadeem Anwar, David Kleesattel, Kenneth E. Sherman – 30 June 2020 – Despite adverse effects like hyperglycemia, new‐onset diabetes after transplant (NODAT), and infectious complications, corticosteroid use remains an important part of liver transplantation (LT) immune suppression. Budesonide, a synthetic corticosteroid, undergoes extensive first‐pass hepatic metabolism with only 10% systemic bioavailability, providing an opportunity for an improved toxicity‐therapeutic ratio.